Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: A case report and review of the literature

Journal of Chemotherapy

Volumn 16, Issue 6, 2004, Pages 599-603

  Díaz, Roberto ^a   Segura, A ^a   Aparicio, J ^a   Calderero, V ^a   Guerrero, A ^a   Pellin L ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

5 fluorouracil; Chemotherapy; Colorectal cancer; Dihydropyrimidine dehydrogenase; Toxicity

Indexed keywords

AMIKACIN; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BILIRUBIN; CEFEPIME; CREATININE; DIHYDROFLUOROURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; DOPAMINE; DRUG METABOLITE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; MESSENGER RNA; NORADRENALIN; PRODRUG; SORIVUDINE; STEROID; THYMIDINE;

ADULT; ALOPECIA; ANEMIA; APHAGIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CASE REPORT; CLINICAL FEATURE; CLINICAL PROTOCOL; COLORECTAL CANCER; DIARRHEA; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG METABOLISM; DRUG UTILIZATION; ENZYME DEFICIENCY; ENZYME MECHANISM; ERYTHEMA; FEMALE; FOLLICULITIS; HAIR LOSS; HAND FOOT SYNDROME; HUMAN; INCIDENCE; LEUKOPENIA; MOUTH ULCER; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROTOXICITY; REVIEW; RISK FACTOR; SKIN EXFOLIATION; SKIN TOXICITY; STOMATITIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 12544258457     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.6.599     Document Type: Review

References (28)

1. Meta-analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16: 3537-3541.
2. th Edition. New York: Springer, 2002.
3. Sloan JA, Loprinzi CL, Novotny PJ, Okuno S, Nair S, Barton DL. Sex differences in fluorouracil-induced stomatitis. J Clin Oncol 2000; 18; 412-420.
4. Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 2002; 20: 1491-1498.
5. Etienne MC, Lagrange JL, Dassonville O, et al. A population study of dyhidropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12: 2248-2253.
6. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency. J Clin Invest 1996; 98: 610-615.
7. Morrison GB, Bastian A, Dela Rosa T, Diasio RB, Takimoto CH. Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Oncol Nurs Forum 1997; 24: 83-88.
8. Tuchman M, Stoeckeler JS, Kiang DT, O'Dea RF, Ramnaraine ML, Birkin BL. Familiar pyrimidenia and pyrimidinuria associated severe fluorouracil toxicity. N Eng J Med 1985; 313: 245-249.
9. Harris BE, Song R, Soon SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protacted continuous infusion. Cancer Res 1990; 50: 197-201.
10. Fleming RA, Milano GA, Gaspard MH, Bargnoux PJ, Thyss A, Plagne R. Dihydropyrimidine dehydrogenase in cancer patients. Eur J Cancer 1993; 29: 740-744.
11. Houyau P, Gay C, Chatelut E, Canal P, Roche H, Milano G. Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J Natl Canc Inst 1993; 85: 1602-1603.
12. Takimoto CH, Lu ZH, Zhang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 1996; 2; 477-481.
13. Johnson MR, Hageboutros A, Wang K, Higj L, Smith JB, Diasio RB. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999; 5: 2006-2011.
14. Milano G, Etienne M, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Reneé N. Dihydropyrimidine dehydrogenase and fluorouracil-related toxicity. Br J Cancer 1999; 79: 627-630.
15. Van Kuilenburg ABP, Vreken P, Abeling NGGM, et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 1999; 104: 1-9.
16. Watabe T, Okuda H, Ogura K. Lethal drug interactions of the new antiviral, sorivudine, with anticancer prodrugs of 5-fluorouracil. Yagugaku Zasshi 1997; 117: 910-921.
17. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified patients and clinical implications in 5-fluorouracil chemotherapy. Cancer Res 1993; 53: 5433-5438.
18. Fleming RA, Milano G, Thyss A, et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fiuorouracil fluorouracil in cancer patients. Cancer Res 1992; 52: 2899-2902.
19. Di Paolo A, Danesi R, Falcone A, et al. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 2001; 12: 1301-1306.
20. Van Kuilenburg ABP, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000; 6: 4705-4712.
21. Lu Z, Zhang R, Diasio RB. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther 1995; 53: 5433-5438.
22. Van Kuilenburg ABP, De Abreu RA, Van Gennip AH. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem 2003; 40: 41-45.
23. Di Paolo A, Danesi R, Vannozzi F, Falcone A, Mini E, Cionini L et al. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. Clin Pharmacol Ther 2002; 72: 627-637.
24. Bocci G, Danesi R, Di Paolo A, et al. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res 2000; &: 3032-3037.
25. Wei X, Elizondo G, Sapone A, et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 1998; 51: 391-400.
26. Van Kuilenburg ABP, Meinsma R, Zoetekouw L, Van Gennip AH. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+IG>A mutation. Int J Cancer 2002; 101: 253-258.
27. Van Kuilenburg ABP, Muller EW, Hassjes J, et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14 + IG-A mutation causing DPD deficiency. Clin Cancer Res 2001; 7: 1149-1153.
28. Raidia M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU) related toxicity compared to controls. Clin Cancer Res 2001; 7: 2832-2839.